2024-12-16 - Analysis Report
## Vertex Pharmaceuticals Inc. (VRTX) Investment Report

**1. Performance Comparison & Company Overview:**

Vertex Pharmaceuticals Inc. is a biotechnology company focused on the discovery, development, and commercialization of innovative therapies for cystic fibrosis and other serious diseases.

Compared to the S&P 500 (VOO), VRTX has significantly outperformed over the analyzed period.  The cumulative return for VRTX is 164.76%, while the S&P 500's is 120.91%. This represents a difference of 43.8 percentage points.  The relative divergence of 68.7% indicates that this outperformance is relatively high compared to the historical range of divergence between the two.


**Alpha and Beta Analysis:**

The provided data shows high CAGR (Compound Annual Growth Rate) with varying MDD (Maximum Drawdown) and Alpha values.  The Beta consistently remains around 0.1, suggesting low correlation with the overall market.  Market capitalization has grown significantly over the period. Notably, the 2019-2021 period shows a negative CAGR, highlighting periods of underperformance.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 48.0% | 21.7% | 19.0% | 0.1 | 39.0 |
| 2016-2018  | 66.0% | 11.0% | 47.0% | 0.1 | 43.0 |
| 2017-2019  | 88.0% | 11.0% | 57.0% | 0.1 | 56.0 |
| 2018-2020  | 17.0% | 22.8% | -10.0% | 0.1 | 61.0 |
| 2019-2021  | -9.0% | 22.8% | -80.0% | 0.1 | 57.0 |
| 2020-2022  | 10.0% | 22.8% | 2.0% | 0.1 | 74.0 |
| 2021-2023  | 84.0% | 9.6% | 60.0% | 0.1 | 105.0 |
| 2022-2024  | 98.0% | 9.6% | 60.0% | 0.1 | 119.0 |


**2. Recent Price Movement:**

* **Closing Price:** $463.73
* **5-Day Moving Average:** $467.87
* **20-Day Moving Average:** $462.14
* **60-Day Moving Average:** $471.55

The price is currently below its 5-day and 60-day moving averages, but above its 20-day moving average, suggesting a potential short-term downward trend, but a longer-term upward trend.


**3. Technical Indicators & Expected Return:**

* **RSI:** 59.28 (Slightly above neutral, suggesting neither overbought nor oversold conditions)
* **PPO:** 0.16 (Positive, indicating bullish momentum)
* **Relative Strength Change (20-day):** +1.4 (Short-term upward trend)
* **Expected Return (2+ years):** 82.3% (Significant outperformance compared to the S&P 500)

The current price of $463.73 does not suggest any extreme price movement (neither a sharp rebound nor a sharp decline) based on the provided data.


**4. Recent Earnings Analysis:**

The earnings data shows significant variability in EPS.  While revenue shows a generally upward trend, EPS fluctuates considerably.  There is no information provided to determine whether these results beat or missed expectations.  Further information would be needed for a full analysis.


| Date       | EPS    | Revenue      |
|------------|--------|--------------|
| 2024-11-05 | 4.05   | $2.77B       |
| 2024-08-02 | -13.92 | $2.65B       |
| 2024-05-07 | 4.26   | $2.69B       |
| 2023-11-07 | 4.01   | $2.48B       |
| 2024-11-05 | 4.01   | $2.48B       | *(Duplicate entry)*


**5. Financial Information:**

**Revenue and Profitability:** Revenue has shown relatively consistent growth, while profit margins have remained strong and relatively stable, though slightly decreased recently.

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-09-30 | $2.77B | 85.84% |
| 2024-06-30 | $2.65B | 85.94% |
| 2024-03-31 | $2.69B | 87.27% |
| 2023-12-31 | $2.52B | 85.38% |
| 2023-09-30 | $2.48B | 87.17% |


**Capital and Profitability:** Equity shows some fluctuation, and ROE (Return on Equity) demonstrates significant volatility, with a notably negative value in Q2 2024.  Further investigation into the causes of this negative ROE is necessary.

| Quarter | Equity    | ROE      |
|---------|-----------|----------|
| 2024-09-30 | $15.63B  | 6.69%    |
| 2024-06-30 | $14.77B  | -24.32%  |
| 2024-03-31 | $18.55B  | 5.93%    |
| 2023-12-31 | $17.58B  | 5.51%    |
| 2023-09-30 | $16.51B  | 6.27%    |


**6. News and Recent Issues:**

This section requires information on recent news headlines, market outlook, and analyst opinions, which was not provided.


**7. Overall Analysis:**

VRTX has demonstrated strong historical outperformance compared to the S&P 500.  Technical indicators suggest a slightly bullish short-term trend, but the price is currently below some of its moving averages.  The company shows consistent revenue growth and high profit margins. However,  the significant volatility in EPS and ROE necessitates further analysis to understand the underlying drivers and potential risks.  Missing information regarding recent news and analyst opinions prevents a fully comprehensive assessment.  More information on earnings expectations and the causes of the negative ROE in Q2 2024 is critical.


**8. Disclaimer:** This report is for informational purposes only and does not constitute financial advice.  Investment decisions should be based on thorough due diligence and consideration of individual risk tolerance.
